Mission Creek Capital Partners Inc. Sells 565 Shares of Johnson & Johnson (NYSE:JNJ)

Mission Creek Capital Partners Inc. lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 28,243 shares of the company’s stock after selling 565 shares during the period. Johnson & Johnson accounts for about 1.1% of Mission Creek Capital Partners Inc.’s portfolio, making the stock its 24th biggest position. Mission Creek Capital Partners Inc.’s holdings in Johnson & Johnson were worth $4,577,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently modified their holdings of the company. McElhenny Sheffield Capital Management LLC boosted its position in shares of Johnson & Johnson by 164.4% during the 2nd quarter. McElhenny Sheffield Capital Management LLC now owns 5,518 shares of the company’s stock worth $806,000 after acquiring an additional 3,431 shares in the last quarter. MADDEN SECURITIES Corp acquired a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $981,000. Guinness Asset Management LTD increased its stake in shares of Johnson & Johnson by 30.8% in the 2nd quarter. Guinness Asset Management LTD now owns 1,266,158 shares of the company’s stock valued at $185,043,000 after purchasing an additional 298,063 shares during the last quarter. Butensky & Cohen Financial Security Inc. raised its holdings in shares of Johnson & Johnson by 2.3% during the 2nd quarter. Butensky & Cohen Financial Security Inc. now owns 24,769 shares of the company’s stock worth $3,620,000 after buying an additional 549 shares in the last quarter. Finally, Guinness Atkinson Asset Management Inc lifted its position in shares of Johnson & Johnson by 26.3% during the 2nd quarter. Guinness Atkinson Asset Management Inc now owns 6,150 shares of the company’s stock worth $899,000 after buying an additional 1,282 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on JNJ shares. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Wells Fargo & Company raised their target price on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Royal Bank of Canada upped their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Citigroup boosted their price objective on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Finally, Guggenheim increased their target price on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Seven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.67.

Johnson & Johnson Trading Down 1.6 %

NYSE:JNJ opened at $152.31 on Wednesday. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85. The firm’s fifty day moving average is $158.77 and its 200-day moving average is $156.45. The firm has a market cap of $366.70 billion, a P/E ratio of 22.04, a P/E/G ratio of 2.75 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business’s revenue was up 5.2% compared to the same quarter last year. During the same period last year, the business posted $2.66 EPS. Equities analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.26%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.